From Nasdaq: 2025-04-29 23:10:00

Eli Lilly (NYSE:LLY) is set to report earnings on May 1, 2025. Historical data shows LLY stock tends to rise post-earnings, with a positive one-day return in 55% of cases, and a median return of 4.5%. Consensus estimates project earnings per share at $3.46 on revenues of $12.72 billion, driven by strong sales of obesity drug Zepbound and Mounjaro.

Understanding these patterns can inform trading strategies, either by establishing a position before earnings to benefit from potential gains, or by analyzing correlations between immediate and medium-term returns for better positioning. The company currently has a market cap of $789 billion, with $45 billion in revenue over the past year, generating an operating profit of $18 billion and a net income of $11 billion.

A strategy to minimize risk involves understanding correlations between short-term and medium-term returns post-earnings. Eli Lilly’s peer performance can also impact stock reactions, with pricing-in potentially starting before earnings are announced. Investors seeking lower volatility than individual stocks can explore alternative investment options like the Trefis High Quality portfolio, which has outperformed the S&P 500 and delivered returns exceeding 91% since inception.



Read more at Nasdaq: How Will Eli Lilly Stock React To Its Upcoming Earnings?